Clinical Trials

Find a Trial

Trial Results

8 protocol(s) meet the specified criteria
14-006OPEN TO ACCRUAL
CLINICAL VALIDATION OF A URINE-BASED ASSAY WITH GENOMIC AND EPIGENOMIC MARKERS FOR PREDICTING RECURRENCE DURING SURVEILLANCE FOR NON-MUSCLE INVASIVE BLADDER CANCER
ASG-22CE-13-2OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
GU14-188OPEN TO ACCRUAL
Phase Ib/II Study of Neoadjuvant Pembrolizumab (MK-3475) with Gemcitabine-Cisplatin (cisplatin eligible) or Gemcitabine (cisplatin-ineligible) in Subjects with T2-4aN0M0 Urothelial Cancer
IUSCC-0552OPEN TO ACCRUAL
A Pilot Study Evaluating a Novel Magneto-Fluidic System for Ultra-High Throughput Detection of Circulating Tumor Cells in Patients with Metastatic and Loco-regional Urothelial Bladder Cancer
IUSCC-0584OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY FOR THE GENITOURINARY ONCOLOGY PROGRAM
IUSCC-0588OPEN TO ACCRUAL
Glycosylation of exosomes in prostate and urothelial carcinoma
NKTR16-214-02OPEN TO ACCRUAL
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-214 AND NIVOLUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
WO29636OPEN TO ACCRUAL
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER SURGICAL RESECTION